Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 1
2009 2
2010 1
2011 1
2012 3
2013 4
2014 4
2015 2
2016 1
2017 7
2018 6
2019 2
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Among authors: delmar p. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y. Alzheimers Res Ther. 2017. PMID: 29221491 Free PMC article. Clinical Trial.
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, Wang G, Bateman R, Kerchner GA, Baudler M, Fontoura P, Doody R. Klein G, et al. Among authors: delmar p. Alzheimers Res Ther. 2019 Dec 12;11(1):101. doi: 10.1186/s13195-019-0559-z. Alzheimers Res Ther. 2019. PMID: 31831056 Free PMC article.
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS. Klughammer B, et al. Among authors: delmar p. J Thorac Oncol. 2016 Apr;11(4):545-55. doi: 10.1016/j.jtho.2015.12.107. Epub 2016 Jan 8. J Thorac Oncol. 2016. PMID: 26773740 Free article.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M. Dimier N, et al. Among authors: delmar p. Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18. Blood. 2018. PMID: 29255066 Free article. Clinical Trial.
An industry statistician's perspective on PHC drug development.
Fridlyand J, Yeh RF, Mackey H, Bengtsson T, Delmar P, Spaniolo G, Lieberman G. Fridlyand J, et al. Among authors: delmar p. Contemp Clin Trials. 2013 Nov;36(2):624-35. doi: 10.1016/j.cct.2013.04.006. Epub 2013 May 3. Contemp Clin Trials. 2013. PMID: 23648396 Review.
Genetic markers of bevacizumab-induced hypertension.
Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Lambrechts D, et al. Among authors: delmar p. Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21. Angiogenesis. 2014. PMID: 24558090
A statistician's perspective on biomarkers in drug development.
Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J; PSI Biomarker Special Interest Group. Jenkins M, et al. Among authors: delmar p. Pharm Stat. 2011 Nov-Dec;10(6):494-507. doi: 10.1002/pst.532. Epub 2011 Dec 8. Pharm Stat. 2011. PMID: 22162336 Review.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page